PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$36.42
+0.07%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$36.41
From 52W high−0.01%
Volume1.82M
Market cap$1.45B
P/E (TTM)103.4x
P/S (TTM)1.9x
Div yield—
Key dataNov 4, 2026
Open
$36.41
From 52W high
−0.01%
Volume
1.82M
Market cap
$1.45B
ValuationView details →
P/E (Fwd)
11.3x
EV/EBITDA
14.1x
P/E (TTM)
103.4x
RSI (14)
83.1
MomentumView details →
1D Return
+0.07%
YTD Return
+40.67%
SummaryUpdated Jun 1, 2026
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a Tampa, Florida-based specialty pharmaceutical company founded in 2006 that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. Originally incorporated as Pacira Pharmaceuticals, the company rebranded to Pacira BioSciences in April 2019 to reflect its expanded focus beyond traditional pharmaceuticals into innovative biotechnology solutions. The company went public in February 2011 and has established itself as a leader in the non-opioid pain management space, addressing the critical need for alternatives to opioid-based treatments in surgical and chronic pain settings.
Similar companies
Latest newsMore news →
Halper Sadeh LLC said it is investigating whether Pacira BioSciences and its board violated their duties in connection with Pacira’s sale to Viatris for $36.50 per share in cash.4d agoBrodsky & Smith announced an investigation into potential claims against Pacira BioSciences' board concerning its proposed sale to Viatris.27d agoPacira BioSciences, Inc. shares surged 44.3% in premarket trading.27d ago